Rallybio (RLYB) Interest & Investment Income (2020 - 2026)
Rallybio (RLYB) posted Interest & Investment Income of $201000.0 for Q1 2026, down 64.11% sequentially from $560000.0 in Q4 2025, and down 68.79% YoY from $644000.0 in Q1 2025.
Rallybio (RLYB) Interest & Investment Income (2020 - 2026) Analysis & Trends
Rallybio has reported Interest & Investment Income for 7 years, with the latest figure at $201000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 68.79% year-over-year to $201000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 51.28% YoY) and the FY2025 annual result came in at $2.2 million, down 48.08% from the prior year.
- Interest & Investment Income eased to $201000.0 in Q1 2026 per RLYB's latest filing, from $560000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.6 million in Q2 2023 and troughed at $97000.0 in Q1 2022.
- A 5-year average of $865647.1 and a median of $811000.0 in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2026: Interest & Investment Income jumped 8825.0% in 2022, then plunged 68.79% in 2026.
- Over 5 years, Interest & Investment Income stood at $1.1 million in 2022, then soared by 35.2% to $1.4 million in 2023, then plunged by 43.99% to $811000.0 in 2024, then slumped by 30.95% to $560000.0 in 2025, then tumbled by 64.11% to $201000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $201000.0, $560000.0, and $462000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 218,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218,000.00 |
| Mar 31, 2026 | 201,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | 462,000.00 |
| Jun 30, 2025 | 523,000.00 |
| Mar 31, 2025 | 644,000.00 |
| Dec 31, 2024 | 811,000.00 |
| Sep 30, 2024 | 986,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.55 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 525,000.00 |
| Jun 30, 2022 | 270,000.00 |
| Mar 31, 2022 | 97,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 12,000.00 |